Skip to content
Open access

Ruxolitinib Cream Improves Clinical Outcomes in Moderate-to-Severe Non-Atopic Chronic Hand Eczema: Responses by Subtype

Nov 2026 · SKIN The Journal of Cutaneous Medicine · 0 citations

Abstract

Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5% ruxolitinib cream twice daily (BID) demonstrated tolerability and efficacy at Week 16, with improvements maintained to Week 32 with as-needed BID treatment. This post hoc analysis evaluated clinical outcomes by CHE subtype. Adults with CHE, Investigator’s Global Assessment (IGA)-CHE score of 3/4 (moderate/severe), CHE-related Itch Numerical Rating Scale score ≥4, and no atopic dermatitis were randomized 1:1 to 1.5% ruxolitinib cream or vehicle BID for 16 weeks of double-blind treatment. All patients then applied 1.5% ruxolitinib cream to active lesions BID as needed in a 16-week open-label extension. Outcomes included achievement of an IGA-CHE score of 0/1 (clear/almost clear) with a ≥2-grade improvement from baseline (IGA-CHE treatment success [IGA-CHE-TS]) and a ≥75%/≥90% improvement from baseline in Hand Eczema Severity Index (HECSI-75/HECSI-90). As-observed outcomes were evaluated descriptively by CHE subtype. Among 186 randomized patients (allergic contact dermatitis [ACD], n=30; contact urticaria/protein contact dermatitis [CU/PCD], n=1; hyperkeratotic eczema, n=26; irritant contact dermatitis [ICD], n=51; vesicular eczema, n=28; unclassified, n=60; subtypes not mutually exclusive), greater IGA-CHE-TS response rates were observed at Week 16 with ruxolitinib cream versus vehicle across etiologic and clinical subtypes (ACD, 46.7% vs 20.0%; hyperkeratotic eczema, 63.6% vs 16.7%; ICD, 56.0% vs 9.1%; vesicular eczema, 61.5% vs 0%; unclassified, 61.5% vs 15.4%); the 1 patient with CU/PCD (randomized to ruxolitinib cream) did not achieve IGA-CHE-TS at Week 16 but did so at Week 32. HECSI-75 and HECSI-90 response rates were also substantially greater at Week 16 with ruxolitinib cream versus vehicle across subtypes. At Week 32, responses were maintained or further improved with as-needed treatment for most subtypes and endpoints, and patients who crossed over from vehicle had substantially improved responses. In summary, ruxolitinib cream improved clinical outcomes in patients with moderate-to-severe CHE in all evaluated subtypes. These results, in combination with existing data in atopic hand eczema, support ruxolitinib cream as a potential treatment option for patients with CHE irrespective of subtype. (Funding, Incyte Corporation).

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.